共 50 条
- [41] THE VALUE OF COMPLEMENT ACTIVATION PRODUCTS IN THE ASSESSMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS FLARES CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 74 (03): : 283 - 288
- [45] SYSTEMIC LUPUS-ERYTHEMATOSUS (CLINICAL FORMS, DIAGNOSIS AND TREATMENT) LILLE MEDICAL, 1980, 25 (08): : 458 - 463
- [46] Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases FRONTIERS IN IMMUNOLOGY, 2024, 15
- [47] Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus LUPUS SCIENCE & MEDICINE, 2016, 3 (01):
- [49] Cell bound complement activation products alone and in combination with low serum complement C3 or C4 have superior diagnostic performance in systemic lupus erythematosus JOURNAL OF IMMUNOLOGY, 2019, 202 (01):